Market capitalization | $3.72b |
Enterprise Value | $3.32b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 9.48 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-781.27m |
Free Cash Flow (TTM) Free Cash Flow | $-485.24m |
Cash position | $437.10m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
13 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
13 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
Jun '24 | |
Current assets | 511 511 |
Fixed assets | 71 71 |
Total Assets | 583 583 |
Jun '24 | |
Equity | 384 384 |
Debt capital | 199 199 |
Total Capital | 583 583 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
Head office | Virgin Islands, British |
CEO | Vladimir Coric |
Employees | 239 |
Founded | 2022 |
Website | www.biohaven.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.